Suchbegriff wählen

academia

Zentiva Advances Pharmaceutical Research Through ORBIS Project

Prague (ots/PRNewswire) - One of the missions that Zentiva has consistently pursued is to connect Academia and the Pharmaceutical Industry to accelerate drug development innovation and meet the unmet needs of the patients. Our company is pleased to resume the scientific exchange program as part of the ORBIS project, which was created within the largest EU grant programs HORIZON 2020, to connect European and American universities with Industrial partners at the scientific level. Thanks to the experience gained in the

Abcam completes $340m strategic acquisition and expands kit capacity and capability

Cambridge, England (ots/PRNewswire) - - Completing $340m strategic acquisition of BioVision - Expanding facilities in Eugene, further growing kits and assays portfolio - Supporting the growing demand of the sector and accelerating execution of strategic plan Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announces the successful completion of its acquisition of BioVision and the expansion of its immunoassay capacity in Eugene, OR. Across the life sciences sector, the

Can European Solutions Allow Equal Access to Rare Disease Drugs in All European Countries?

Wien (OTS) - The pool of patients suffering from an individual rare disease is very small. Drug development in this area is complex and the risk of failure is much higher than for other diseases. Basic research and the search for treatment options is neglected and often not deemed worth the investment. Ninety-five percent of all rare diseases are still without any treatment options. On October 1, 2021, panelists at the European Health Forum Gastein took a closer look at this issue and discussed potential future

Can European Solutions Allow Equal Access to Rare Disease Drugs in All European Countries?

Wien (OTS) - The pool of patients suffering from an individual rare disease is very small. Drug development in this area is complex and the risk of failure is much higher than for other diseases. Basic research and the search for treatment options is neglected and often not deemed worth the investment. Ninety-five percent of all rare diseases are still without any treatment options. On October 1, 2021, panelists at the European Health Forum Gastein took a closer look at this issue and discussed potential future

SC Johnson Invites Londoners to Walk Beneath the Ocean’s Surface in The Blue Paradox – An Immersive Experience Exploring the…

London (ots/PRNewswire) - Two-week educational event opens to the public (15-27th September) in White City, with free tickets available at BlueParadox.com SC Johnson, the maker of household consumer brands such as Mr Muscle®, Ecover® and Duck®, is launching The Blue Paradox, an immersive educational experience with 360-degree digital projections that invites the public to walk beneath the ocean's surface to explore the impact plastic waste has on our planet's most valuable natural resource and to better understand how

100+ Global Enterprises Take Advantage of Infosys Living Labs to Accelerate their Digital Innovation Agenda

Bengaluru, India (ots/PRNewswire) - Infosys Living Labs is delivering digital innovation as-a-service to help them meet next normal consumer expectations Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced that Infosys Living Labs is driving the digital innovation agenda for over 100 global enterprises. With Infosys Living Labs, businesses can leverage on-demand multi-tiered digital infrastructure, comprising technology, processes, people,

Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity

Darmstadt, Germany (ots/PRNewswire) - - Merck to support up to six additional research projects at the BioMed X Institute in Heidelberg within the next six years - Call for application for a global crowdsourcing project, 'Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging' Merck, a leading science and technology company, today announced the extension of its ongoing collaboration with BioMed X, Heidelberg, Germany. Under the new agreement, Merck will start up to six additional research projects at the

Infosys and Ellen MacArthur Foundation Partner to Drive Forward Circular Economy

London (ots/PRNewswire) - Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, has partnered with the Ellen MacArthur Foundation charity. The organisations will work together to accelerate the global transition to a circular economy. The Foundation works with its Network of Strategic Partners, Partners, and Members. Infosys has joined the Network as a Partner. The Network includes some of the world's leading and most influential organisations, including businesses, governments,

G20 at a Glance: The role of the civil society in the G20 Process

Riyadh, Saudi Arabia (ots/PRNewswire) - The G20 has a strong tradition of working with a broad range of organizations to bring different perspectives on socioeconomic challenges to the G20 table. The Engagement Groups are independent collectives that are led by civil society organizations and the business sector from the host country. They work with other organizations from G20 countries to develop policy recommendations that are formally submitted, through the G20 Presidency, to G20 leaders for consideration.

Launched Today: Infosys Cobalt – A Set of Services, Solutions, and Platforms for Enterprises to Accelerate their Cloud Journey

Bengaluru, India (ots/PRNewswire) - - Offers over 14,000 cloud assets and over 200 industry cloud solution blueprints Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, today launched Infosys Cobalt - a set of services, solutions, and platforms that acts as a force multiplier for cloud-powered enterprise transformation. Infosys Cobalt helps businesses redesign the enterprise, from the core, and also build new cloud-first capabilities to create seamless experiences in public,

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny